GottfriedEKonecnyMD

Oncology • Los Angeles, CA

Gynecologic Cancer

Associate Professor, Medicine, University of California Los Angeles David Geffen SOM

Join to view full profile

Dr. Konecny is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Konecny's full profile

Already have an account?

Office
100 UCLA Medical Plz Ste 550
Los Angeles, CA 90024
Phone+1 310-206-1214

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gynecologic Oncology, 2005 - 2007
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 2013 - 2026

Clinical Trials

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer Start of enrollment: 2009 Jan 01
Terminated
Phase 2
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer Start of enrollment: 2009 Jan 01
Completed
Phase 2
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Completed
Phase 2
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression Start of enrollment: 2011 Dec 15
Completed
Phase 2
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer Start of enrollment: 2019 Mar 06
Active, not recruiting
Phase 2
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer Start of enrollment: 2020 Oct 16
Recruiting
Phase 2
PRO1184 for Advanced Solid Tumors Start of enrollment: 2022 Dec 07
Recruiting
Phase 1, Phase 2
Roles: Contact
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Start of enrollment: 2023 Jan 11
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025.
Jordyn Silverstein, Beth Karlan, Nasim Herrington, Gottfried Konecny
Current Opinion in Obstetrics & Gynecology. 2025-02-01
1 citations
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, Amit Oza, Nicoletta Colombo
Gynecologic Oncology. 2024-12-01
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer.
Lora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, Collin M Coon, Saranya Rajendran
Biorxiv. 2024-10-21

Press Mentions

Targeted Therapy for Early Breast Cancer and Advances in PSMA PET Scans at ASCOMay 22nd, 2023
UCLA Joins Clinical Trial to Study COVID-19 in People with CancerSeptember 15th, 2020
OncLive® Presents State of the Science Summit™ on Ovarian CancerJune 17th, 2019
Join now to see all

Other Languages

German